Core Viewpoint - Virax Biolabs Group Limited has successfully closed a private placement raising $5 million, which will extend its cash runway into the first half of 2028, supporting ongoing regulatory studies related to long COVID and other immune-related conditions [1][3]. Financial Details - The company sold 12,500,000 ordinary shares and preferred investment options at a combined price of $0.3999 per pre-funded warrant, with an exercise price of $0.0001 per share for the pre-funded warrants [2]. - The preferred investment options have an exercise price of $0.40 per ordinary share and are exercisable for five years from the effective date of the Initial Registration Statement [2]. Use of Proceeds - The net proceeds from the offering will be utilized for general working capital needs, allowing the company to continue its studies on post-acute sequelae of COVID-19 and post-acute infection syndrome [3]. Regulatory Compliance - The securities offered were part of a private placement exempt from registration under the Securities Act of 1933, and the company plans to file an Initial Registration Statement with the SEC for the resale of the ordinary shares [4]. Investment Options Adjustment - The company has agreed to reduce the exercise price of its outstanding Series A and Series B Preferred Investment Options from $2.934 to $0.40 per share and extend their term to the fifth anniversary of the effective date of the Initial Registration Statement [5]. Company Overview - Virax Biolabs Group Limited focuses on the detection of immune responses and diagnosis of viral diseases, developing T cell-based test technologies aimed at addressing chronic conditions linked to immune dysregulation, such as Long COVID [7].

Core Viewpoint - Virax Biolabs Group Limited has announced a private placement for the purchase and sale of 12,500,000 ordinary shares at a price of $0.40 per share, aiming to raise gross proceeds of $5 million for working capital and corporate purposes [1] Group 1: Private Placement Details - The private placement includes ordinary shares and preferred investment options to purchase an additional 12,500,000 ordinary shares [1] - The exercise price for the preferred investment options is set at $0.40 per ordinary share, exercisable immediately for five years [1] - H.C. Wainwright & Co. is the exclusive placement agent for this offering [1] Group 2: Financial Implications - The expected gross proceeds from the private placement are $5 million, before deducting fees and expenses [1] - The company plans to use the net proceeds for working capital and other general corporate purposes [1] Group 3: Regulatory and Compliance Aspects - The securities involved in this transaction are not registered under the Securities Act of 1933 and cannot be reoffered or resold in the U.S. without proper registration or exemption [1] - Virax has agreed to file an initial registration statement with the SEC for the resale of the ordinary shares issued to investors [1] Group 4: Company Overview - Virax Biolabs Group Limited focuses on immunology research and diagnostics, particularly in the detection of immune responses to viral diseases [1] - The company is developing T cell-based test technologies aimed at diagnosing conditions like Long COVID and other chronic immune-related issues [1]